General
Preferred name
Y-27632
Synonyms
Y-27632 dihydrochloride ()
Y-27632 2HCl ()
Y 27632 dihydrochloride ()
Y-27632 (dihydrochloride) ()
Y-27632 (hydrochloride) ()
Y27632 ()
Y-27632-d4 (hydrochloride hydrate) ()
P&D ID
PD004560
CAS
129830-38-2
146986-50-7
Tags
available
drug candidate
Drug Status
experimental
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Y-27632 dihydrochloride is an orally active and ATP-competitive ROCK (Rho-kinase) inhibitor (ROCK-I Ki=220 nM; ROCK-II Ki=300 nM). Y-27632 dihydrochloride shows antiepileptic effects[1][2][3][4].
PRICE 43
DESCRIPTION We represent the compound as drawn in the article by Wu et al (2010) . Note that the PubChem entry for this compound is missing stereochemistry. (GtoPdb)
DESCRIPTION Y-27632 is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation[1][2][3][4][5][6][7].
PRICE 32
DESCRIPTION Glucosidase I and II inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Selective p160ROCK inhibitor (Tocriscreen Total)
DESCRIPTION Y-27632 dihydrochloride (Y-27632 2HCl) is an orally potent, ATP-competitive inhibitor of ROCK-I and ROCK-II. Y-27632 dihydrochloride also inhibits isolation-induced apoptosis in mouse prostate stem or progenitor cells. (TargetMol Bioactive Compound Library)
DESCRIPTION Y-27632 is an orally potent, ATP-competitive inhibitor of ROCK-I and ROCK-II. Y-27632 also inhibits isolation-induced apoptosis in mouse prostate stem or progenitor cells. (TargetMol Bioactive Compound Library)
Cell lines
1
Organisms
1
Compound Sets
17
Axon Medchem Screening Library
1683
Cayman Chemical Bioactives
10005583
42454
Concise Guide to Pharmacology 2017/18
5290
Concise Guide to Pharmacology 2019/20
5290
Concise Guide to Pharmacology 2021/22
5290
Concise Guide to Pharmacology 2023/24
5290
Drug Repurposing Hub
DrugBank
DB08756
EU-OPENSCREEN Bioactive Compound Library
EOS101041
Guide to Pharmacology
5290
MedChem Express Bioactive Compound Library
HY-10583
HY-10071
Novartis Chemogenetic Library (NIBR MoA Box)
Selleckchem Bioactive Compound Library
Y-27632
y-27632-rock
TargetMol Bioactive Compound Library
T1725
T1870
Tocris Bioactive Compound Library
1254
Tocriscreen Total
ZINC Tool Compounds
ZINC000100002002
External IDs
42
Properties
(calculated by RDKit )
Molecular Weight
247.17
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
2
Aromatic Ring Count
1
cLogP
2.17
TPSA
68.01
Fraction CSP3
0.57
Chiral centers
1.0
Largest ring
6.0
QED
0.86
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Apoptosis
ROCK
ROCK1 (p160ROCK)
ROCK2
ROCK1
PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2
ROCK inhibitor
Autophagy,ROCK
Organoid
Primary Target
Rho-Kinases
MOA
Inhibitor
Calcium Sensitizers
Rho Kinase 2 (ROCK 2| ROCKalpha) Inhibitors
Rho Kinase 1 (ROCK 1| p160-ROCK) Inhibitors
Leucine-Rich Repeat Kinase 2 (LRRK2| Dardarin) Inhibitors
rho associated kinase inhibitor
Member status
member
Pathway
Cell Cycle/DNA Damage
cytoskeleton
Stem Cell/Wnt
TGF-beta/Smad
Cell Cycle/Checkpoint
Cytoskeletal Signaling
Stem Cells
Source data